Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Bromazolam demonstrates abuse potential comparable to other benzodiazepines. Drug discrimination studies in rats showed full dose-dependent substitution for midazolam, with an ED50 of 0.54 mg/kg, indicating significant reinforcing properties mediated through α1 subunit binding.
Physical dependence develops with regular use, similar to prescription benzodiazepines. Chronic use leads to neuroadaptation requiring continued dosing to avoid withdrawal symptoms.
Benzodiazepine-like compounds including bromazolam are rarely fatal when taken alone, but can cause severe central nervous system depression when combined with other depressant medications or drugs.
At high doses, bromazolam may induce delirium and auditory or visual hallucinations. These effects are dose-dependent and not typically observed at standard doses.
While bromazolam possesses anticonvulsant properties at typical doses, high doses may paradoxically induce seizures. Benzodiazepine withdrawal is also associated with seizure risk, though specific data for bromazolam is limited.
Bromazolam was first synthesized in 1976 as part of benzodiazepine research, representing a structural modification of alprazolam where the chlorine atom is replaced with bromine. Despite its early synthesis, the compound was never developed as a pharmaceutical product or brought to market for…
Classified as a Class C controlled substance under UK drug control legislation. Class C represents the lowest tier of controlled substances, with possession, supply, and production without authorization constituting criminal offenses.
Currently unscheduled at the federal level. Pursuant to a Drug Enforcement Administration notice, bromazolam will be placed into Schedule I on January 14, 2026 for two years with a possible one-year extension. Several states, including Virginia, have independently classified bromazolam as Schedule I at the state level, though notably excluding the related analog phenazolam. Despite its current federal unscheduled status, arrests have occurred for mismarketing bromazolam as alprazolam in counterfeit Xanax-shaped tablets, resulting in counterfeit drug charges. The U.S. Department of Justice reported in June 2022 that bromazolam seizures were surging nationwide, frequently detected alongside fentanyl in the illicit drug supply.
18 sources cited